CARLSBAD, Calif., Dec. 18, 2020
CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of common stock, (ii) 1,000,000 pre-funded common stock Warrants (i.e., warrants to purchase shares of Qualigen common stock, for which the exercise price is almost entirely prepaid), (iii) 1,348,314 two-year common stock Warrants with an exercise price of $4.07 per share, and (iv) 842,696 common stock Warrants (first exercisable 6 months after issuance, and with an expiration date 30 months after issuance) with an exercise price of $4.07 per share.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The securities were sold pursuant to an effective shelf registration statement on Form S-3 (File No. 333-232798) previously filed with the U.S. Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. |